(NASDAQ: PVLA) Palvella Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Palvella Therapeutics's earnings in 2026 is -$49,297,000.On average, 18 Wall Street analysts forecast PVLA's earnings for 2026 to be -$75,813,405, with the lowest PVLA earnings forecast at -$95,299,593, and the highest PVLA earnings forecast at -$51,956,952. On average, 18 Wall Street analysts forecast PVLA's earnings for 2027 to be -$87,885,777, with the lowest PVLA earnings forecast at -$154,475,298, and the highest PVLA earnings forecast at -$23,192,379.
In 2028, PVLA is forecast to generate -$50,207,125 in earnings, with the lowest earnings forecast at -$158,270,415 and the highest earnings forecast at $45,782,358.